Patent · US Active

Macrocylic pyrimidine derivatives

US10017509B2 · kind B2 · utility

0Cited by

0References

12Claims

0Family size

Assignee

Janssen Pharmaceuticals, Inc. · BE

Inventors

Gaston Stanislas Marcella Diels · Turnhout, BE
Bruno Schoentjes · Bois-Guillaume, FR
Matthias VERSELE · Leuven, BE
Didier Jean-Claude Berthelot · Edegem, BE
Marc Willems · Beerse, BE
Marcel Viellevoye · Breda, NL
Werner Constant Johan Embrechts · Beerse, BE
Berthold Wroblowski · Vosselaar, BE
Lieven Meerpoel · Beerse, BE

Key dates

Filing date	Apr 2, 2015
Grant date	Jul 10, 2018
Priority date	—
Expiry date	Apr 2, 2035

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02P20/582
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to substituted macrocylic pyrimidine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention have EF2K inhibitory activity and optionally also Vps34 inhibitory activity. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.